title: Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients.
abstract: Hyperphosphatemia is a common feature of advanced chronic kidney disease (CKD) and is treated routinely with oral calcium-based phosphate binders. In 2003, the National Kidney Foundation Kidney Disease Outcomes and Quality Initiative (K/DOQI) published Clinical Practice Guidelines (CPGs) for the treatment of Bone Metabolism and Disease in CKD. These advocate broad usage of expensive non-calcium-based phosphate binders such as sevelamer. This study was designed to determine the cost of implementation of the K/DOQI CPGs as they pertain to phosphate binding in a large Canadian hemodialysis (HD) unit. Laboratory and medication data for all chronic HD patients at the Ottawa Hospital were reviewed (n=416). Patients meeting each of the relevant K/DOQI guidelines were identified. Where guidelines would recommend a switch to non-calcium binders, equivalent sevelamer doses were estimated. The cost of implementing each guideline was then calculated individually and an estimate total cost of implementing all the guidelines was derived. Overall, 53% (222) patients fulfilled at least one criterion for sevelamer use. The yearly cost of implementation of the K/DOQI guidelines at this center was estimated at 500,605 dollars (American dollars). Given the significant cost, widespread adoption of the K/DOQI CPGs for Bone Metabolism and Disease should await the publication of compelling data demonstrating significant improved outcomes in patients treated with sevelamer.
authors.affiliation: Division of Nephrology, Department of Medicine, Queen's University, Kingston, Ontario, Canada. cw38@post.queensu.ca
authors.forename: C A
authors.initials: CA
authors.lastname: White
authors.forename: J
authors.initials: J
authors.lastname: Jaffey
authors.forename: P
authors.initials: P
authors.lastname: Magner
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000191:economics / Q000209:etiology; D002614:Chelating Agents / Q000191:economics* / Q000627:therapeutic use; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000191:economics; D008297:Male; D008875:Middle Aged; D011073:Polyamines / Q000191:economics* / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis; D000069603:Sevelamer
chemical_list: D002614:Chelating Agents; D011073:Polyamines; D000069603:Sevelamer